{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:25:31Z","timestamp":1793496331671,"version":"4.5.0"},"reference-count":7,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T00:00:00Z","timestamp":1723939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T00:00:00Z","timestamp":1723939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fluid overload (FO) commonly occurs during hospitalization for allogeneic hematopoietic cell transplantation (HCT). Grade 2\u20134 FO is associated with day +100 non-relapse mortality.1 Post-transplant cyclophosphamide (PTCY) for graft-versus-host disease prevention requires aggressive IV hydration to prevent hemorrhagic cystitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      This is a single-center, retrospective, observational study conducted at an academic medical center via electronic chart review. Included patients received allogeneic HCT followed by PTCY on days +3 and +4. Patients were excluded for age &lt; 18 years or incarceration. Primary endpoints are incidence of Grade 2\u20134 FO and associated risk factors. Descriptive and inferential statistics (i.e.,\n                      <jats:bold>Fisher's exact test<\/jats:bold>\n                      ,\n                      <jats:bold>multivariable regression analysis) were<\/jats:bold>\n                      used.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 97 patients screened, 95 were included and 2 were excluded due to absence of weight measurements needed to grade FO. Median age was 60 years, 66.3% were male, 91.6% received reduced-intensity conditioning, 72.6% received haploidentical HCT, 44.2% were ECOG 0, and 11.6% had diastolic dysfunction. Incidence of grade 2\u20134 FO was 33.7% (n\u2009=\u200932). Univariate analyses found age (continuous; p\u2009=\u20090.04) and BSA &lt; 1.7\u2005m\n                      <jats:sup>2<\/jats:sup>\n                      (p\u2009=\u20090.006) as independent factors associated with grade 2\u20134 FO. Multivariable regression analysis found 3.3% higher risk with every 1-year increase in age ranging from f 20 to 78 years (OR 1.033, 95% CI 1.001, 1.006; p\u2009=\u20090.0453) and 82.8% lower risk with BSA \u2265 1.7\u2005m\n                      <jats:sup>2<\/jats:sup>\n                      (OR 0.172, 95% CI 0.051, 0.588; p\u2009=\u20090.005) after adjusting for co-variates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion(s)<\/jats:title>\n                    <jats:p>\n                      Increasing age and BSA\u2009&lt;\u20091.7\u2005m\n                      <jats:sup>2<\/jats:sup>\n                      are risk factors associated with grade 2\u20134 FO during hospitalization for allogeneic HCT with PTCY.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241276418","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T02:46:25Z","timestamp":1724035585000},"page":"1046-1050","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of fluid overload in allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7321-952X","authenticated-orcid":false,"given":"Megan","family":"Tsao","sequence":"first","affiliation":[{"name":"University of California, Davis Health (UCDH)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Hoeg","sequence":"additional","affiliation":[{"name":"University of California, Davis Health (UCDH)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Pecoraro","sequence":"additional","affiliation":[{"name":"University of California, Davis Health (UCDH)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Kuehner","sequence":"additional","affiliation":[{"name":"University of California, Davis Health (UCDH)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Deen","sequence":"additional","affiliation":[{"name":"University of California, Davis Health (UCDH)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Guglielmo","sequence":"additional","affiliation":[{"name":"University of California, Davis Health (UCDH)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,8,18]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.08.021"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215943"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.012"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.228"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.031"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01364-0"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241276418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241276418","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241276418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:13Z","timestamp":1777689013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241276418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":7,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10781552241276418"],"URL":"https:\/\/doi.org\/10.1177\/10781552241276418","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,18]]}}}